Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?-Reference-Cited by-同舟云学术

Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

Published:2017-02-09 Issue:5 Volume:40 Page:373-386
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Shah Rashmi R.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

http://link.springer.com/content/pdf/10.1007/s40264-017-0508-3.pdf

Reference148 articles.

1. Shah RR. Hyperglycaemia induced by novel anticancer agents: an undesirable complication or a potential therapeutic opportunity? Drug Saf. 2016. doi: 10.1007/s40264-016-0485-y .

2. European Medicines Agency. Approval of nintedanib (VARGATEF) for NSCLC (21 November 2014). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002569/WC500173607.pdf . Accessed 21 July 2016.

3. Shah RR. Tyrosine kinase inhibitors-induced interstitial lung disease: clinical features, diagnostic challenges and therapeutic dilemmas. Drug Saf. 2016;39:1073–91.

4. Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf. 2013;36:413–26.

5. Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013;11:172–91.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Posterior reversible encephalopathy syndrome associated with use of anlotinib to treat squamous cell carcinoma of the cervix: case report and literature review;Frontiers in Pharmacology;2023-12-15

2. Posterior Reversible Encephalopathy Syndrome after Pazopanib Therapy;Diseases;2023-05-23

3. Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review;Frontiers in Pharmacology;2023-02-06

4. Posterior reversible encephalopathy syndrome and autoimmunity;Autoimmunity Reviews;2023-02

5. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma;Brain Sciences;2022-12-23